Savara (SVRA) Assets Average (2011 - 2026)
Savara (SVRA) reported Assets Average of $237.5 million for Q1 2026, up 18.12% year-over-year from $201.1 million in Q1 2025, and up 20.47% on a QoQ basis from $197.2 million in Q4 2025.
Savara (SVRA) has 16 years of Assets Average data on file, last reported at $237.5 million in Q1 2026.
- Quarterly Assets Average rose 18.12% year-over-year to $237.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.5 million (up 18.12% YoY) and the FY2025 annual result came in at $233.2 million, up 19.43% from the prior year.
- Assets Average improved to $237.5 million in Q1 2026 per SVRA's latest filing, from $197.2 million in the prior quarter.
- Across five years, Assets Average topped out at $237.5 million in Q1 2026 and bottomed at $124.6 million in Q2 2023.
- The 5-year median for Assets Average is $167.9 million (2024), against an average of $171.5 million.
- The widest annual swing landed in 2023, when Assets Average decreased 22.85%; it then gained 25.6% in 2024.
- Tracing SVRA's Assets Average over 5 years: stood at $143.8 million in 2022, then increased by 25.08% to $179.8 million in 2023, then gained by 25.6% to $225.8 million in 2024, then slipped by 12.69% to $197.2 million in 2025, then increased by 20.47% to $237.5 million in 2026.
- Per Business Quant, the three latest SVRA Assets Average figures stand at $237.5 million (Q1 2026), $197.2 million (Q4 2025), and $152.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 237.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 237.54 Mn |
| Dec 31, 2025 | 197.18 Mn |
| Sep 30, 2025 | 152.34 Mn |
| Jun 30, 2025 | 176.54 Mn |
| Mar 31, 2025 | 201.10 Mn |
| Dec 31, 2024 | 225.85 Mn |
| Sep 30, 2024 | 189.24 Mn |
| Jun 30, 2024 | 148.98 Mn |
| Mar 31, 2024 | 167.93 Mn |
| Dec 31, 2023 | 179.82 Mn |
| Sep 30, 2023 | 150.95 Mn |
| Jun 30, 2023 | 124.60 Mn |
| Mar 31, 2023 | 134.57 Mn |
| Dec 31, 2022 | 143.77 Mn |
| Sep 30, 2022 | 152.27 Mn |
| Jun 30, 2022 | 161.49 Mn |
| Mar 31, 2022 | 171.40 Mn |
| Dec 31, 2021 | 181.94 Mn |
| Sep 30, 2021 | 191.85 Mn |
| Jun 30, 2021 | 202.03 Mn |
| Mar 31, 2021 | 152.69 Mn |
| Dec 31, 2020 | 103.54 Mn |
| Sep 30, 2020 | 112.24 Mn |
| Jun 30, 2020 | 117.56 Mn |
| Mar 31, 2020 | 128.09 Mn |
| Dec 31, 2019 | 138.42 Mn |
| Sep 30, 2019 | 143.98 Mn |
| Jun 30, 2019 | 147.80 Mn |
| Mar 31, 2019 | 150.28 Mn |
| Dec 31, 2018 | 153.71 Mn |
| Sep 30, 2018 | 136.53 Mn |
| Jun 30, 2018 | 123.41 Mn |
| Mar 31, 2018 | 144.25 Mn |
| Dec 31, 2017 | 139.26 Mn |
| Sep 30, 2017 | 122.33 Mn |
| Jun 30, 2017 | 69.83 Mn |
| Mar 31, 2017 | 21.41 Mn |
| Dec 31, 2016 | 34.53 Mn |
| Sep 30, 2016 | 43.90 Mn |
| Jun 30, 2016 | 48.91 Mn |
| Mar 31, 2016 | 52.18 Mn |
| Dec 31, 2015 | 58.83 Mn |
| Sep 30, 2015 | 60.10 Mn |
| Jun 30, 2015 | 59.74 Mn |
| Mar 31, 2015 | 66.61 Mn |
| Dec 31, 2014 | 63.33 Mn |
| Sep 30, 2014 | 57.77 Mn |
| Jun 30, 2014 | 60.86 Mn |
| Mar 31, 2014 | 58.80 Mn |
| Dec 31, 2013 | 57.45 Mn |
| Sep 30, 2013 | 61.74 Mn |
| Jun 30, 2013 | 53.08 Mn |
| Mar 31, 2013 | 44.65 Mn |
| Dec 31, 2012 | 49.27 Mn |
| Sep 30, 2012 | 52.87 Mn |
| Jun 30, 2012 | 55.85 Mn |
| Mar 31, 2012 | 59.68 Mn |
| Dec 31, 2011 | 54.07 Mn |
| Sep 30, 2011 | 48.22 Mn |